News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
258,946 Results
Type
Article (13827)
Company Profile (293)
Press Release (244826)
Section
Business (79301)
Career Advice (147)
Deals (13176)
Drug Delivery (31)
Drug Development (50262)
Employer Resources (31)
FDA (5668)
Job Trends (5108)
News (144017)
Policy (10013)
Tag
Academia (901)
Alliances (21438)
Alzheimer's disease (729)
Approvals (5631)
Artificial intelligence (59)
Bankruptcy (97)
Best Places to Work (4457)
Biotechnology (241)
Breast cancer (57)
Cancer (573)
Cardiovascular disease (52)
Career advice (128)
CAR-T (44)
Cell therapy (149)
Clinical research (39581)
Collaboration (202)
Compensation (83)
COVID-19 (998)
C-suite (53)
Cystic fibrosis (61)
Data (612)
Diabetes (64)
Diagnostics (1191)
Earnings (28575)
Events (46502)
Executive appointments (154)
FDA (5911)
Funding (207)
Gene editing (48)
Gene therapy (127)
GLP-1 (290)
Government (1063)
Healthcare (6527)
Infectious disease (1027)
Inflammatory bowel disease (89)
IPO (7168)
Job creations (859)
Job search strategy (124)
Layoffs (181)
Legal (1372)
Lung cancer (101)
Manufacturing (66)
Medical device (2547)
Medtech (2548)
Mergers & acquisitions (6087)
Metabolic disorders (203)
Neuroscience (909)
NextGen Class of 2024 (1996)
Non-profit (841)
Northern California (782)
Obesity (117)
Opinion (90)
Parkinson's disease (55)
Patents (45)
People (24888)
Pharmaceutical (48)
Phase I (13911)
Phase II (18404)
Phase III (11681)
Pipeline (139)
Postmarket research (846)
Preclinical (5870)
Radiopharmaceuticals (203)
Rare diseases (140)
Real estate (1409)
Regulatory (8159)
Research institute (930)
Southern California (722)
Startups (1963)
United States (6578)
Vaccines (153)
Weight loss (74)
Date
Today (173)
Last 7 days (505)
Last 30 days (1816)
Last 365 days (20669)
2024 (17675)
2023 (22412)
2022 (26822)
2021 (27806)
2020 (23357)
2019 (16224)
2018 (11738)
2017 (13745)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (146)
Asia (16764)
Australia (2819)
California (1773)
Canada (645)
China (134)
Colorado (65)
Connecticut (71)
Europe (36076)
Florida (191)
Georgia (51)
Illinois (111)
Indiana (51)
Kansas (54)
Maryland (259)
Massachusetts (1478)
Michigan (45)
Minnesota (82)
New Jersey (482)
New York (540)
North Carolina (381)
Northern California (782)
Ohio (72)
Pennsylvania (374)
South America (207)
Southern California (722)
Texas (181)
Washington State (197)
258,946 Results for "palvella therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer
October 17, 2024
·
7 min read
Press Releases
Palvella Therapeutics Announces Presentations at the 12th Pediatric Dermatology Research Alliance (PeDRA) Annual Conference
October 15, 2024
·
8 min read
Press Releases
Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement
July 24, 2024
·
22 min read
Press Releases
Palvella Therapeutics Awarded Up to $2.6 million Grant from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development to Support Phase 3 Single-Arm, Baseline-Controlled Trial in Microcystic Lymphatic Malformations
October 3, 2024
·
9 min read
Business
Palvella Therapeutics and Ligand Pharmaceuticals Expand Strategic Partnership to Accelerate Phase 3 Development of QTORIN™ rapamycin for Microcystic Lymphatic Malformations and Additional High Unmet Need Clinical Indications
Palvella Therapeutics, Inc. today announced the expansion of their strategic partnership to accelerate Phase 3 development of QTORIN™ rapamycin for the treatment of Microcystic Lymphatic Malformations (Microcystic LMs).
December 1, 2023
·
4 min read
FDA
Palvella Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations
Palvella Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to QTORIN rapamycin™ for the treatment of Microcystic Lymphatic Malformations (Microcystic LMs).
November 16, 2023
·
4 min read
Drug Development
Palvella Therapeutics Reports Topline Results from Pivotal Phase 3 VAPAUS Study of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Pachyonychia Congenita
Palvella Therapeutics, Inc. today announced topline results from VAPAUS, a 24-week, randomized, double-blind, placebo-controlled pivotal Phase 3 study of QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for the treatment of Pachyonychia Congenita (PC).
July 20, 2023
·
3 min read
Drug Development
Palvella Therapeutics Announces Planned Pivotal Phase 3 Study Design of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations
Palvella Therapeutics, Inc. today announced the planned pivotal Phase 3 study design of QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin), a topical mTOR inhibitor and the lead product candidate from the QTORIN™ platform, in Microcystic Lymphatic Malformations (Microcystic LMs).
July 20, 2023
·
9 min read
Pharm Country
Palvella Therapeutics Announces Pipeline Update on QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ Rapamycin) for Serious, Rare Genetic Skin Diseases with No FDA-approved Therapies
Palvella Therapeutics, Inc. today reported progress on its three lead development programs for QTORIN™ rapamycin.
February 21, 2023
·
9 min read
Drug Development
Palvella Therapeutics Announces Positive Topline Results from Phase 2 Study of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations
Palvella Therapeutics, Inc. today announced positive topline results from the Company’s Phase 2 study of QTORIN™ rapamycin in Microcystic Lymphatic Malformations (Microcystic LM). Microcystic LM is a rare, chronically debilitating genetic disease caused by dysregulation of the PI3K/mTOR pathway.
March 9, 2023
·
6 min read
1 of 25,895
Next
